AbCellera Biologics, Inc. ABCL 深 沪
交易中 06-26 11:22:55 美东时间
7.00
+0.330
+4.95%
华盛通- 最 高7.07
- 今 开6.49
- 成交量 431.50万股
- 最 低 5.47
- 昨 收 6.67
- 总市值 199.50万
- 52周最高 7.07
- 市盈率 静 14.52
- 换手率 1514.03%
- 52周最低 2.745
- 委 比 -40.85%
- 总股本 0.00亿
- 历史最高 71.91
- 量 比 2.07
- 振 幅 23.99%
- 历史最低 1.10
- 每 手 1
- 风险率 0.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
Jazz Pharmaceuticals teams with AbCellera on cancer therapies as analysts maintain positive targets despite a recent Zepzelca trial setback.
06-18 00:54
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
AbCellera Biologics's Earnings Outlook
AbCellera Biologics (NASDAQ:ABCL) is set to give its latest quarterly earnings ...
02-24 05:02
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. UBS analyst Leonardo Olmos downgraded the rating for Globant S.A. (NYSE:GLOB) from Buy to Neutral, while raise...
2024-08-20 21:45
Benchmark Downgrades AbCellera Biologics to Hold From Buy
06:33 AM EDT, 08/20/2024 (MT Newswires) -- AbCellera Biologics (ABCL) has an average buy rating and a price target range of $5 to $28, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia a...
2024-08-20 18:33
